About PIQUR
PIQUR is a company based in Basel (Switzerland) founded in 2011. PIQUR has raised $54.12 million across 4 funding rounds from investors including Versant Ventures and Eurostars. The company has 1 employees. PIQUR operates in a competitive market with competitors including Daré Bioscience, Atossa Therapeutics, Olema Oncology, Minerva Biotechnologies and Puma Biotechnology, among others.
- Total Equity Funding$54.12M (USD)
in 4 rounds
- Latest Funding Round$18.98M (USD), Series A
Jul 2015
- InvestorsVersant Ventures
& 1 more
- Employee Count1
Funding Insights of PIQUR
PIQUR has successfully raised a total of $54.12M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $18.98 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $54.12M
- Total Rounds 4
- Last Round Series A — $18.98M
- Investors Count 2
All 4 funding rounds of PIQUR with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2015 | $18.98M | Series A | – | Versant Ventures | – |
| Jan 2014 | $35.14M | Series A | – | Versant Ventures | – |
| Sep 2013 | – | Seed | – | – | – |
| Jun 2013 | – | Grant | – | – |
2 investors in total: 2 institutional.
Investors in PIQUR
PIQUR has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Versant Ventures and Eurostars.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - | |
- | – | eurostars-eureka.eu | - |
Investor details for PIQUR
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of PIQUR
3 dated milestones of PIQUR across 4 years, from founding to its latest funding, stage changes and deals.
- Founded PIQUR is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $19.0M.
Competitors of PIQUR
PIQUR operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Atossa Therapeutics, Olema Oncology, Minerva Biotechnologies and Puma Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| darebioscience.com | 2005 | San Diego, United States | – | 30 | Non-hormonal pharmaceutical products for female contraceptives are developed. | |
| atossatherapeutics.com | 2009 | Seattle, United States | $13.52M | 10 | Drugs for breast cancer treatment and prevention are developed. | |
| olema.com | 2007 | San Francisco, United States | $139M | 74 | Drug therapeutics for breast cancer treatment are developed. | |
| minervabio.com | 1999 | Waltham, United States | $18.86M | – | Cell therapy and antibodies are developed to treat cancer. | |
| pumabiotechnology.com | 2010 | Los Angeles, United States | $60M | 193 | Tyrosine kinase inhibitors for breast cancer are developed. | |
| ambagontx.com | 2020 | San Francisco, United States | $108M | – | Small-molecule therapeutics for cancer treatment are developed. | |
| mab-works.com | 2003 | Beijing, China | $214.44M | – | Anticancer therapies are developed using a dual-function antibody platform. | |
| eikonoklastes.com | 2019 | Columbus, United States | $20.76M | 3 | Tissue factor targeting therapeutics for cancer treatment are developed. | |
| greenwichlifesciences.com | 2019 | Houston, United States | – | 3 | Peptide-based immunotherapy for breast cancer treatment is developed. |
Detailed competitors of PIQUR
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Piqur
Complete news archive for PIQUR
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to PIQUR
10 companies that operate in the same segment as PIQUR (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PIQUR
PIQUR was founded in 2011 and raised its 1st funding round 2 years after it was founded.
PIQUR is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
PIQUR is a funded company, having raised a total of $54.12M across 4 funding rounds to date.
PIQUR has 1 employees.
PIQUR was founded in 2011 in Basel, Switzerland, within the biotechnology sector. Focus is placed on the discovery and development of anti-cancer therapeutics that inhibit lipid kinase (PI3K) and mTOR pathways. The lead candidate, PQR309, a small-molecule pan-PI3KmTOR inhibitor, is advanced in phase 2 clinical trials for lymphomas and solid tumors. Operations center on oncology drug innovation for potential therapeutic applications.
PIQUR's top competitors include Atossa Therapeutics, Daré Bioscience and Puma Biotechnology.
PIQUR has 2 investors. Key investors include Versant Ventures, and Eurostars.